Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Apoptotic chromatin condensation inducer 1 (ACIN1) encodes the nuclear protein Acinus, a multifunctional factor initially discovered for its involvement in apoptosis, primarily inducing chromatin condensation after activation by caspase-3, without direct DNA fragmentation[1][3][5]. Acinus is also an essential regulator of alternative splicing, acting within spliceosome-associated multiprotein complexes such as the exon junction complex (EJC) and the ASAP complex, which integrate cell death signals with gene expression programs[1][2][3]. Loss of ACIN1 is embryonic lethal, underscoring its developmental importance; tissue-specific knockout studies demonstrate effects on muscle regeneration and splicing of muscle-related genes[2]. Post-translational modifications (phosphorylation by Akt and SRPK2) influence its stability and apoptotic function, especially in cancer cell contexts[1]. While ACIN1 plays dual roles in cell death and RNA processing, there is currently no evidence that it is a direct therapeutic target or clinical biomarker[1][2][3][5].
Not applicable. Drugs do not directly target ACIN1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Apoptotic chromatin condensation inducer 1 (ACIN1).